INFECTIOUS DISEASE RESEARCH INSTITUTE Patent applications |
Patent application number | Title | Published |
20150182612 | COMPOSITIONS AND METHODS FOR TREATING AN ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION - The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active | 07-02-2015 |
20150087615 | COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING METASTASIS - Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker. | 03-26-2015 |
20150017200 | FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the | 01-15-2015 |
20140341970 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 11-20-2014 |
20140322268 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS - Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: | 10-30-2014 |
20140193459 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 07-10-2014 |
20140050776 | NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION - The present invention is directed to methods of preventing reactivation of active and latent | 02-20-2014 |
20140037691 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 02-06-2014 |
20130345079 | MYCOBACTERIUM TUBERCULOSIS ANTIGENS AND COMBINATIONS THEREOF HAVING HIGH SEROREACTIVITY - The present invention relates to compositions and fusion proteins containing comprising | 12-26-2013 |
20130273094 | VACCINES AGAINST TOXOPLASMA GONDII - Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is | 10-17-2013 |
20130209500 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 08-15-2013 |
20130177584 | Recombinant Polyprotein Vaccines For the Treatment and Diagnosis of Leishmaniasis - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 07-11-2013 |
20130084307 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 04-04-2013 |
20130071862 | FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the | 03-21-2013 |
20130058997 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 03-07-2013 |
20120114688 | VACCINES COMPRISING NON-SPECIFIC NUCLEOSIDE HYDROLASE AND STEROL 24-C-METHYLTRANSFERASE (SMT) POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising | 05-10-2012 |
20120039994 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 02-16-2012 |
20110280902 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more | 11-17-2011 |
20110070290 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 03-24-2011 |
20110014274 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 01-20-2011 |
20100317607 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS - Compounds of a compound of compound of general formula (I) wherein X | 12-16-2010 |
20100310602 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS - Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: | 12-09-2010 |
20100136046 | RECOMBINANT POLYPROTEIN VACCINES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 06-03-2010 |
20100129391 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 05-27-2010 |
20100008924 | FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the | 01-14-2010 |
20090291099 | RECOMBINANT POLYPROTEIN VACCINES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 11-26-2009 |
20090041798 | LEISHMANIA STEROL 24-C-METHYLTRANSFERASE COMPOSITIONS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise | 02-12-2009 |
20080287362 | Compositions and Methods for the Detection of Trypanosoma Cruzi Infection - Compositions comprising fusion polypeptides of | 11-20-2008 |